Loading...

A THERAPEUTIC OX40 AGONIST DYNAMICALLY ALTERS DENDRITIC, ENDOTHELIAL AND T CELL SUBSETS WITHIN THE ESTABLISHED TUMOR MICROENVIRONMENT

Little preclinical modeling currently exists to support the use of OX40 agonists as therapeutic agents in the setting of advanced cancers, as well as, the mechanisms through which therapeutic efficacy is achieved. We demonstrate that treatment of mice bearing well-established day 17 sarcomas with a...

Full description

Saved in:
Bibliographic Details
Main Authors: Pardee, Angela D., McCurry, Dustin, Alber, Sean, Hu, Peisheng, Epstein, Alan L., Storkus, Walter J.
Format: Artigo
Language:Inglês
Published: 2010
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3058673/
https://ncbi.nlm.nih.gov/pubmed/21045144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-1369
Tags: Add Tag
No Tags, Be the first to tag this record!